HALO (Halozyme Therapeutics) Cyclically Adjusted Book per Share: $1.65 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HALO Halozyme Therapeutics Inc HALO
91 GF Score
Price $100.65
GF Value $96.97
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Cyclically Adjusted Book per Share?

Halozyme Therapeutics HALO -1.11% 91 Cyclically Adjusted Book per Share is $1.65 as of Jun. 2026. GuruFocus rates HALO with a GF Score™ of 91/100 and a GF Value™ of $96.97 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Halozyme Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was $1.259. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.65 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Halozyme Therapeutics's average Cyclically Adjusted Book Growth Rate was 15.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 19.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 19.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 18.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Halozyme Therapeutics was 31.00% per year. The lowest was -5.30% per year. And the median was 17.80% per year.

As of today (2026-08-14), Halozyme Therapeutics's current stock price is $100.65. Halozyme Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $1.65. Halozyme Therapeutics's Cyclically Adjusted PB Ratio of today is 61.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Halozyme Therapeutics was 79.11. The lowest was 25.64. And the median was 45.04.


Halozyme Therapeutics  (NAS:HALO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Halozyme Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=100.65/1.65
=61.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Halozyme Therapeutics was 79.11. The lowest was 25.64. And the median was 45.04.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Halozyme Therapeutics Cyclically Adjusted Book per Share Related Terms


Halozyme Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Cyclically Adjusted Book per Share Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 0.90 1.03 1.26 1.54

Halozyme Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 1.54 1.54 1.60 1.65

HALO vs NUVL, KRYS, IONS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted PB Ratio falls into.


HALO
91GF Score
Halozyme Therapeutics Inc HALO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Halozyme Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.259/333.9520*333.9520
=1.259

Current CPI (Jun. 2026) = 333.9520.

Halozyme Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 -0.093 241.428 -0.129
201612 -0.251 241.432 -0.347
201703 -0.451 243.801 -0.618
201706 0.410 244.955 0.559
201709 0.509 246.819 0.689
201712 1.459 246.524 1.976
201803 1.842 249.554 2.465
201806 1.768 251.989 2.343
201809 1.659 252.439 2.195
201812 1.720 251.233 2.286
201903 1.789 254.202 2.350
201906 1.783 256.143 2.325
201909 1.675 256.759 2.179
201912 0.671 256.974 0.872
202003 0.429 258.115 0.555
202006 0.772 257.797 1.000
202009 0.731 260.280 0.938
202012 1.119 260.474 1.435
202103 0.471 264.877 0.594
202106 0.842 271.696 1.035
202109 1.998 274.310 2.432
202112 1.432 278.802 1.715
202203 1.887 287.504 2.192
202206 2.129 296.311 2.399
202209 0.717 296.808 0.807
202212 1.256 296.797 1.413
202303 0.500 301.836 0.553
202306 1.145 305.109 1.253
202309 1.887 307.789 2.047
202312 0.661 306.746 0.720
202403 1.398 312.332 1.495
202406 2.287 314.175 2.431
202409 3.559 315.301 3.770
202412 2.955 315.605 3.127
202503 3.915 319.799 4.088
202506 2.829 322.561 2.929
202509 4.288 324.800 4.409
202512 0.414 324.054 0.427
202603 1.853 330.213 1.874
202606 1.259 333.952 1.259

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1.65 mean?
Halozyme Therapeutics (HALO) has a Cyclically Adjusted Book per Share of $1.65 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Cyclically Adjusted Book per Share too high?
Halozyme Therapeutics' current Cyclically Adjusted Book per Share is $1.65. Overall, Halozyme Therapeutics has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Cyclically Adjusted Book per Share compare to NUVL and KRYS?
Halozyme Therapeutics' Cyclically Adjusted Book per Share of $1.65 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Cyclically Adjusted Book per Share is $1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Fairly Valued. The stock's GF Value™ is $96.97, compared to a current price of $100.65 — trading 3.8% above its estimated fair value. The current Cyclically Adjusted Book per Share is $1.65. Halozyme Therapeutics' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Cyclically Adjusted Book per Share is $1.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued. The current stock price of $100.65 is trading 3.8% above its estimated GF Value™ of $96.97. GuruFocus considers Halozyme Therapeutics to be Fairly Valued.

Key valuation signals for HALO:

  • Cyclically Adjusted Book per Share: $1.65
  • GF Value™: $96.97 vs. price of $100.65 (3.8% above fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
91GF Score

Get the complete analysis for HALO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$100.65
Price
$96.97
GF Value